Company intelligence / Profile preview

RoyaltyRx Capital

Darien, Connecticut, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

RoyaltyRx Capital is a private special opportunities investment firm focused on pharmaceuticals and broader biopharma-related opportunities. The firm appears to operate as a healthcare-focused investment vehicle rather than a drug developer, with activity centered on royalty and special-situation investments in life sciences. Publicly available references link the firm to founder and managing partner Todd C. Davis, a biopharma investor and former co-founder/managing partner of HealthCare Royalty Partners. Available evidence suggests RoyaltyRx Capital was founded in 2018 and is based in Darien, Connecticut. Because the firm is an investor rather than an operating therapeutics company, it does not appear to maintain a conventional R&D pipeline of proprietary drug programs.

Industry: Investors

Beyond the preview

Go deeper on RoyaltyRx Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RoyaltyRx Capital.

Explore the full profile